Novavax | NVAX - Fremdkapital





Fremdkapital Veränderung Datum
Adma Biologics USD 192.84M 745K 2026-06
Agenus USD 153.98M 15.68M 2026-03
AstraZeneca USD 26.01B 46M 2026-06
BioCryst Pharmaceuticals USD 395.4M 203K 2026-06
Cassava Sciences USD 0 0 2024-12
Geron USD 120.13M 298K 2026-06
GlaxoSmithKline GBP 13.95B 65M 2026-06
MannKind USD 545.13M 2.93M 2026-06
Merck USD 51.08B 4.41B 2026-06
Minerva Neurosciences USD 0 86.58M 2024-09
Moderna USD 597M 6M 2026-06
Novartis USD 37.45B 7.86B 2026-03
Novavax USD 246.3M 200K 2025-12
Pfizer USD 60.5B 70M 2026-06
Sanofi EUR 14.65B 806M 2026-06
Sarepta Therapeutics USD 847.62M 9.46M 2026-06
TG Therapeutics USD 745.39M 247K 2026-06